Filing summary
Company identity discrepancy: The supplied filing is for Rosewind Corporation, a development-stage sailing-school business—not Aytu Biopharma, Inc. The filing covers the quarter ended May 31, 2013, the third quarter of Rosewind’s fiscal year ending August 31, 2013. Financial statements are unaudited.
Business context and results
Rosewind intended to teach offshore sailing using its vessel. Operations and revenue remained limited; management said the company had collected full tuition from only three students, while the filing also refers to six students trained. The company reported its fourth training voyage in May 2013.
| Metric | Three months ended May 31, 2013 | Three months ended May 31, 2012 | Nine months ended May 31, 2013 | Nine months ended May 31, 2012 |
|---|---|---|---|---|
| Revenue | $1,750 | $0 | $1,750 | $0 |
| Operating expenses | $13,708 | $11,085 | $45,091 | $39,185 |
| Operating loss | $11,958 | $11,085 | $43,341 | $39,185 |
| Interest expense | $1,307 | $855 | $3,441 | $2,502 |
| Net loss | $13,265 | $11,940 | $46,782 | $41,687 |
Gross margin is not separately reported; the very small revenue base does not provide a meaningful margin measure. Since inception, the company reported $5,250 of revenue, $539,459 of operating expenses, and an accumulated development-stage deficit of $557,668.
Financial position and liquidity
- At May 31, 2013, cash was $728, total assets were $9,441, and total current liabilities were $115,451. Working capital deficit was $114,723.
- Related-party loans payable were $96,142, secured by the sailing vessel, bearing 6% interest and due on demand; accrued related-party interest was $11,910.
- For the nine months, operating cash used was $32,470; investing cash flow was zero; financing cash provided was $33,089, including $28,089 of related-party borrowing and $5,000 from stock issuance. Cash increased by $619.
- Common shares outstanding were 4,889,402 at May 31, 2013. Subsequent to quarter-end, Rosewind issued 8,000 restricted shares for services.
Changes, outlook, and risks
- Nine-month net loss increased $5,095, or 12%, year over year. Management cited higher professional and filing fees, travel and interest costs, partly offset by lower advertising expense.
- Effective May 31, 2013, the letter of intent with Glycomar Limited was terminated.
- Management said current cash was insufficient to sustain the business and intended to seek additional equity funding, with no assurance it could raise funds. The filing warns that the company’s ability to continue as a going concern is uncertain.
- Risks include minimal and unproven student demand, dependence on additional funding and a sole officer/director, potential regulatory and licensing requirements, limited insurance, vessel safety and maintenance costs, and weather and operating hazards. The company estimated public-company costs alone would exceed $25,000 annually.
- No quantified financial guidance was provided. Management cautioned that interim results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Confirm the intended issuer: the filing identifies Rosewind Corporation, not Aytu Biopharma, Inc.
- Reconcile the filing’s differing student counts and assess whether student bookings can support operating costs.
- Review the demand-on-demand related-party loan terms, accrued interest, and the officer’s role as lender and sole director.
- Assess near-term funding needs, the feasibility of raising capital, and the consequences of the terminated Glycomar letter of intent.
- Verify applicable vessel certifications and insurance coverage, given the company’s stated regulatory and liability exposures.